Drug Trial Radar · NCT04336241
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Oct 17, 2019
Primary completion
Oct 31, 2026
Study completion Oct 31, 2026
Sponsor
- Lead sponsor
- Replimune, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RP2-001-18 is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP2 in adult subjects with advanced solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Conditions
- Cancer
Interventions
RP2Biological
Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation
nivolumabBiological
Programmed death receptor (PD-1) blocking antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of adverse events (AEs)Time frame: From Day 1 up to 60 days after last dose
- Percentage of serious adverse events (SAEs)Time frame: From Day 1 up to 60 days after last dose
- Percentage of dose limiting toxicities (DLTs)Time frame: From Day 1 up to 30 days after last dose.
- Percentage of treatment emergent adverse events (TEAEs)Time frame: From Day 1 up to 60 days after last dose.
- Percentage of TEAEs ≥ Grade 3Time frame: From Day 1 up to 60 days after last dose.
- Percentage of events requiring withdrawalTime frame: From Day 1 up to last dose (up to 8 weeks for dose escalation phase and up to 2 years for expansion phase)).
- Maximum tolerated dose (MTD) of RP2Time frame: 7 months
- Recommended Phase 2 dose (RP2D) of RP2Time frame: 7 months
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Hospital Universitario d'Hebron
Barcelona, Spain
Hospital Universitario HM Sanchinarro
Madrid, Spain
Hospital Clinico de Valencia
Valencia, Spain
The Royal Marsden NHS Foundation Trust
London, United Kingdom
Churchill Hospital
Oxford, United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust
Bebington, Merseyside, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.